查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014752

人體生長荷爾蒙市場：按類型、劑型、應用和最終用戶分類－2026-2032年全球市場預測

Human Growth Hormone Market by Type, Dosage Form, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，人體生長荷爾蒙市場價值將達到 67.5 億美元，到 2026 年將成長至 72.5 億美元，到 2032 年將達到 126.3 億美元，複合年成長率為 9.36%。

主要市場統計數據
基準年 2025 67.5億美元
預計年份：2026年 72.5億美元
預測年份 2032 126.3億美元
複合年成長率 (%) 9.36%

對人體生長荷爾蒙療法進行策略性概述，反映臨床進展、監管壓力和影響相關人員決策的商業性因素。

人體生長荷爾蒙）療法融合了內分泌學、生技藥品生產和以患者為中心的給藥模式。過去幾十年，該領域已從以醫院為中心的有限治療模式發展成為一個更廣泛的生態系統，其中重組生產、給藥裝置和循證醫學證據的生成共同決定著臨床應用。這種發展使得治療依從性、裝置人體工學和長期安全性監測的重要性日益凸顯，同時也使該領域面臨更嚴格的監管審查和支付方評估。

臨床、技術和政策主導的變革正在重新定義生長激素治療的治療途徑、交付模式和患者獲得生長激素荷爾蒙療法的機會。

近年來，多種因素共同作用，重塑了人體生長荷爾蒙療法的研發、應用和推廣。生技藥品生產技術的進步降低了生物相似藥的進入門檻，但同時也提高了人們對生產品質和等效性檢測的期望。同時，給藥方式的改進和連線健診工具的應用，使得以病人為中心的治療模式得以超越傳統的臨床診療模式。

對美國關稅措施將如何影響生長激素製劑的供應鏈、採購慣例和臨床取得途徑進行全面評估。

調整跨境關稅和貿易措施的政策干預會對生物製藥的整個治療價值鏈產生重大的下游影響。 2025年的關稅調整可能會影響原料、活性藥物成分和成品給藥裝置，可能會增加製造商和合約研發生產機構（CDMO）的接收成本。反過來，這將影響採購決策和供應商合約。這些趨勢可能促使製造商重新評估供應商多元化策略，加強緩衝庫存策略，並優先考慮關鍵零件的近岸外包，以維持供應的連續性。

詳細的細分分析揭示了產品類型、劑型、臨床應用和醫療保健環境的差異如何影響採用率和營運重點。

對人體生長荷爾蒙市場的細分分析揭示了與產品類型、劑型、臨床應用和醫療環境相關的明確策略意義。在評估產品類型時，新生物相似藥進入者和原廠藥生產商之間的動態會影響定價、醫療專業人員教育和互通性政策決策。生物相似藥往往更注重比較臨床證據和上市後監測，而原廠藥生產商則更著重於生命週期最佳化和品牌差異化。劑型也會影響病人和醫療服務提供者的偏好。藥筒和預填充注射筆提高了易用性，並支持居家給藥，而管瓶在受控的臨床環境和特定給藥需求中仍然發揮著至關重要的作用。

決定全球醫療保健市場進入、購買行為和商業化方式的區域趨勢和跨境政策因素。

區域趨勢對整個醫療保健系統中治療方法的評估、採購和實施方式有顯著影響。在美洲，支付方多元化、私部門的強大影響力以及複雜的報銷機制，使得療效比較證據和病人支持服務的提供至關重要。製造商通常會投資於價值評估文件和支付方溝通策略，以應對不同的保險覆蓋政策，並促進患者在公共和私人醫療項目中獲得治療。

先鋒製造商、生物相似藥開發商、醫療設備創新者和服務供應商之間的競爭與合作策略正在塑造該產業的定位和發展。

人體生長荷爾蒙）領域的競爭格局呈現出多元化的特點，既有成熟的生物製藥公司，也有生物相似藥的參與企業、醫療設備創新者、契約製造和數位醫療服務提供者。每家企業都透過多層次的策略來凸顯自身優勢，這些策略包括累積臨床證據、改進給藥裝置以及建構患者支持生態系統。原廠藥廠透過共同開發器材、進行依從性計畫和進行針對性臨床試驗來提升產品價值，而生物相似藥開發商則專注於等效性、成本效益高的生產方式以及上市後監測，以增強臨床醫生的信心。

為高階主管提供切實可行的策略挑戰，以加強生長激素療法的供應韌性、加速臨床應用並改善以患者為中心的給藥模式。

產業領導者應優先制定一系列切實可行的策略，以增強韌性、加快部署並確保病患安全。首先，應透過採購多元化、建立區域製造夥伴關係關係和策略性庫存規劃來確保供應鏈的柔軟性，從而降低貿易中斷和零件短缺的風險。除了這些營運措施之外，與監管機構的積極合作也至關重要。具體而言，這包括制定清晰的生物相似藥等效性計劃、統一跨司法管轄區的醫療設備驗證策略以及開展上市後核准收集工作。

本研究採用高度透明的混合調查方法，詳細說明了構成本研究基礎的證據來源、相關人員參與、分析框架和檢驗程序。

本報告採用混合方法整合了研究結果，該方法結合了對關鍵相關人員的訪談、監管文件的審查、臨床文獻的彙編以及營運分析。主要研究包括與臨床醫生、保險公司、採購負責人、醫療設備開發商和生產合作夥伴進行結構化討論，以了解目前的決策者和營運限制。此外，還審查了監管指南、附加檔資訊和公開的臨床結果文獻，以確定核准適應症、安全性概況和醫療設備注意事項的基準。

整合策略意義和相關人員可操作的未來路徑，重點在於改善生長激素療法的效果、可及性和商業性永續性。

人體生長荷爾蒙療法的持續進展取決於產業能否將臨床價值、生產可靠性和以患者為中心的服務模式結合。生物相似藥的競爭、醫療設備的創新以及不斷變化的監管預期相互交織，既為生產商、醫療服務提供者和政策制定者帶來了機遇，也帶來了責任。在證據生成和風險分擔方面採取協作方式，對於將治療潛力轉化為永續的患者獲益至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：人體生長荷爾蒙市場：依類型分類

  • 生物相似藥
  • 原廠產品

第9章：以劑型分類的人體生長荷爾蒙市場

  • 墨水匣
  • 預填充筆
  • 管瓶

第10章：人體生長荷爾蒙市場：依應用領域分類

  • 核准的適應症
    • 慢性腎臟病
    • 生長激素缺乏症
    • 普拉德-威利症候群
    • 出生體重偏低，與胎齡相符
    • 透納氏症
  • 仿單標示外用藥
    • 抗衰老
    • 運動能力
    • 健美

第11章：人體生長荷爾蒙市場：以最終用戶分類

  • 居家醫療設施
  • 醫院
  • 專科診所

第12章：人體生長荷爾蒙市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：人體生長荷爾蒙市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：人體生長荷爾蒙市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國人體生長荷爾蒙市場

第16章：中國人體生長荷爾蒙市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Biopartners GmbH
  • Eli Lilly and Company
  • Ferring Pharmaceuticals SA
  • Genetech Inc.
  • Ipsen SA
  • LG Chem, Ltd.
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Roche Holding AG
  • Sandoz International GmbH
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-43127F7278D3

The Human Growth Hormone Market was valued at USD 6.75 billion in 2025 and is projected to grow to USD 7.25 billion in 2026, with a CAGR of 9.36%, reaching USD 12.63 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.75 billion
Estimated Year [2026] USD 7.25 billion
Forecast Year [2032] USD 12.63 billion
CAGR (%) 9.36%

Strategic overview of human growth hormone therapeutics reflecting clinical evolution, regulatory pressures, and commercial drivers shaping stakeholder decisions

Human growth hormone therapeutics occupy a distinctive intersection of endocrinology, biologics manufacturing, and patient-centered delivery models. Over the past decades the field has transitioned from limited, hospital-based therapies toward a broader ecosystem in which recombinant manufacturing, delivery devices, and evidence generation collectively determine clinical adoption. This evolution has elevated the importance of treatment adherence, device ergonomics, and long-term safety monitoring while also exposing the sector to intensified regulatory scrutiny and payer evaluation.

Clinical stakeholders now place greater emphasis on differentiated therapeutic value beyond biochemical endpoints. Real-world evidence is increasingly used to validate outcomes across approved indications and to shape reimbursement discussions. At the same time, device innovation such as prefilled delivery systems and cartridges has reduced barriers to home administration, creating new opportunities and responsibilities for providers and manufacturers alike.

Consequently, commercial strategies must align with clinician workflows, regulator expectations, and patient experience priorities. Successful programs will balance robust clinical evidence and supply reliability with investments in device usability and patient support, thereby creating a durable foundation for sustainable treatment pathways.

Emerging clinical, technological, and policy-driven transformations that are redefining treatment pathways, delivery models, and patient access for growth hormone therapies

Recent years have brought converging shifts that are reshaping how human growth hormone therapies are developed, delivered, and adopted. Advances in biologics manufacturing have lowered barriers for biosimilar entrants while simultaneously raising expectations for manufacturing quality and comparability testing. At the same time, improvements in delivery formats and connected health tools have enabled more patient-centric administration models that extend treatment beyond traditional clinic settings.

Regulatory frameworks are also adapting to these technical and commercial developments. Agencies are clarifying pathways for biosimilarity, device co-development, and post-authorization evidence generation, prompting manufacturers to accelerate life-cycle strategies that combine clinical studies with longitudinal real-world data collection. Payer behaviour has become more evidence-driven, encouraging partnerships that demonstrate measurable clinical and economic benefits.

Together, these shifts underscore a landscape where clinical differentiation, device experience, and evidence continuity create competitive advantage. Organizations that anticipate policy adjustments, invest in adherence-enabling technologies, and integrate robust evidence plans into product launches will be better positioned to meet evolving stakeholder expectations and improve patient outcomes.

Comprehensive assessment of how United States tariff measures interact with supply chains, procurement practices, and clinical access pathways for growth hormone products

Policy interventions that adjust cross-border duties and trade measures can create material downstream effects across the therapeutic value chain for biological products. Tariff changes in 2025 affecting raw materials, active pharmaceutical ingredients, and finished delivery devices can raise landed input costs for manufacturers and contract development and manufacturing organizations, which in turn influence sourcing decisions and supplier contracts. These dynamics often prompt manufacturers to revisit supplier diversification, increase buffer inventory strategies, and prioritize nearshoring for critical components to preserve continuity of supply.

Procurement professionals and hospital systems may respond to tariff-driven cost pressures by renegotiating contracts or shifting toward local suppliers where available, which can alter existing distribution routes and contractual obligations. Device imports such as prefilled pens and cartridge systems are particularly sensitive to cross-border levies, creating incentive to qualify alternative device partners or expand in-region assembly capabilities. Clinical operations are also affected: trial supplies and longer-term adherence programs require predictable logistics, and tariff volatility can complicate planning for multicenter studies and patient support services.

Finally, broader macroeconomic reactions-such as currency fluctuations and trade policy adjustments-can amplify these effects, motivating industry stakeholders to engage proactively with trade compliance experts, invest in flexible manufacturing architectures, and coordinate with payers and providers to mitigate access disruptions while preserving patient care continuity.

In-depth segmentation analysis revealing how differences in product type, dosage delivery, clinical application, and care settings drive adoption and operational priorities

Segmentation in the human growth hormone landscape reveals distinct strategic implications tied to product type, dosage form, clinical application, and care setting. When evaluating product type, the dynamic between biosimilar entrants and originator therapies informs decisions around pricing, clinician education, and interchangeability policies; biosimilars tend to drive attention to comparative clinical evidence and post-market surveillance while originator manufacturers emphasize life-cycle enhancements and brand differentiation. Dosage form also shapes patient and provider preferences; cartridges and prefilled pens improve ease of use and support home administration, whereas vials remain relevant in controlled clinical environments and for specific dosing needs.

Clinical application further segments demand profiles. Approved indications such as chronic kidney disease, growth hormone deficiency, Prader-Willi syndrome, small for gestational age, and Turner syndrome require tailored clinical pathways, long-term monitoring, and multi-stakeholder coordination for pediatric and adult care. Off-label uses, including anti-aging, athletic performance, and bodybuilding, create reputational and safety considerations and drive regulatory and payer scrutiny. End-user settings introduce operational distinctions: home care settings rely on patient education, remote monitoring, and secure delivery logistics, hospitals require institutional procurement and formulary processes, and specialist clinics balance clinical expertise with patient throughput considerations.

Understanding these intersecting segments enables stakeholders to prioritize evidence generation, optimize device selection, and design patient support models that reflect the nuanced needs of each cohort, thereby improving both clinical outcomes and service sustainability.

Regional dynamics and cross-border policy drivers that determine access, purchasing behavior, and commercialization approaches across global healthcare markets

Regional dynamics materially influence how therapies are evaluated, purchased, and administered across healthcare systems. In the Americas, payer fragmentation, a strong private sector presence, and complex reimbursement pathways create an environment where evidence of comparative effectiveness and patient support offerings are decisive. Manufacturers often invest in value dossiers and payer engagement strategies to navigate heterogeneous coverage policies and to facilitate access across private and public programs.

Europe, Middle East & Africa presents a mosaic of regulatory regimes and procurement models. Centralized evaluation bodies and national pricing committees coexist with country-level purchasing authorities, encouraging coordinated evidence generation and adaptive pricing approaches. Supply chain resilience and regional manufacturing partnerships are frequently prioritized to meet diverse regulatory and logistical requirements. In contrast, Asia-Pacific features a combination of high-capacity manufacturing hubs, rapid regulatory modernization in several markets, and expanding patient access initiatives. Local production capabilities and public-private collaborations are shaping routes to broader utilization while also attracting biosimilar investment and device innovation.

Across these regions, cross-border trade policies, regulatory convergence efforts, and local clinical practice patterns interact to define commercialization strategies. Successful regional programs therefore blend global evidence generation with localized pricing, distribution, and patient engagement tactics.

Competitive and collaborative strategies among originator manufacturers, biosimilar developers, device innovators, and service providers shaping industry positioning and growth

Competitive dynamics in the human growth hormone sector are characterized by a mix of established biologics manufacturers, biosimilar entrants, device innovators, contract manufacturers, and digital health providers. Organizations are differentiating through layered strategies that combine clinical evidence development, delivery device enhancements, and patient support ecosystems. Originator firms are extending product value via device co-development, adherence programs, and targeted clinical studies, while biosimilar developers emphasize comparability, cost-effective manufacturing, and post-market surveillance to build clinician confidence.

Strategic partnerships and licensing agreements continue to be prominent as companies seek to accelerate market entry or broaden geographic reach without assuming full-scale manufacturing risk. Device and digital health collaborations are increasingly important; integrating adherence-tracking features and remote monitoring into delivery systems amplifies long-term data capture, which in turn strengthens payer engagement. Contract manufacturing and regional assembly agreements enable flexibility in supply chains, allowing firms to respond to trade policy changes and local procurement preferences.

Leadership teams that combine clinical credibility with agile commercial models and robust supply chain governance tend to preserve competitive positioning. Investing in transparent evidence generation, thoughtful pricing frameworks, and durable provider relationships remains essential to sustaining product uptake and long-term clinical integration.

Actionable strategic imperatives for executives to strengthen supply resilience, accelerate clinical adoption, and elevate patient-centric delivery models in growth hormone care

Industry leaders should prioritize a set of executable strategies to strengthen resilience, accelerate adoption, and protect patient safety. Begin by securing supply chain flexibility through diversified sourcing, regional manufacturing partnerships, and strategic inventory planning to reduce exposure to trade disruptions and component shortages. Pair these operational moves with proactive regulatory engagement: establish clear comparability plans for biosimilars, harmonize device validation strategies across jurisdictions, and commit to post-authorization evidence collection.

Simultaneously, invest in delivery platforms and patient support services that enhance adherence and reduce treatment burden. User-centered device design, training programs for home administration, and integrated digital tools for remote monitoring help improve long-term outcomes and support payer conversations. Commercial strategies should foreground value by aligning evidence generation with payer priorities and by creating tailored contracting models for different end-user settings.

Finally, adopt ethical and governance frameworks to mitigate risks associated with off-label demand. Educate clinicians and patients about approved indications, reinforce safety monitoring, and collaborate with professional societies to uphold clinical standards. By combining operational resilience, evidence-focused commercialization, and patient-centered delivery, organizations can create a sustainable competitive advantage while safeguarding access and clinical integrity.

Transparent mixed-method research methodology detailing evidence sources, stakeholder engagement, analytical frameworks, and validation steps underpinning the study

This report synthesizes findings using a mixed-method approach that integrates primary stakeholder interviews, regulatory document review, clinical literature synthesis, and operational analysis. Primary research included structured discussions with clinicians, payers, procurement professionals, device developers, and manufacturing partners to capture contemporary decision drivers and operational constraints. Regulatory guidance, labeling information, and publicly available clinical outcomes literature were reviewed to establish a baseline of approved indications, safety profiles, and device considerations.

Analytical frameworks combined qualitative thematic analysis with supply chain mapping and comparative device assessments. Evidence triangulation ensured that insights were corroborated across multiple sources, and methodological transparency underpinned how conclusions were drawn from the data. Validation steps encompassed expert peer review and iterative refinement of findings to ensure practical relevance to commercial and clinical stakeholders.

Limitations are acknowledged, including the variability of regional reimbursement policies and the evolving nature of regulatory pathways, which require periodic reassessment. Nonetheless, the methodology emphasizes reproducibility and actionable synthesis to inform strategic planning and operational decision-making.

Synthesis of strategic implications and a pragmatic pathway forward for stakeholders focused on improving outcomes, access, and commercial sustainability in growth hormone therapy

Sustained progress in human growth hormone therapeutics will depend on the sector's ability to align clinical value, manufacturing reliability, and patient-centered delivery. The convergence of biosimilar competition, device innovation, and evolving regulatory expectations creates both opportunities and responsibilities for manufacturers, providers, and policy-makers. Collaborative approaches to evidence generation and risk sharing will prove decisive in translating therapeutic potential into durable patient benefit.

Operationally, resilience in supply chains and the adoption of adherence-supporting delivery formats are essential to preserve continuity of care and to enhance long-term outcomes. Stakeholders who integrate robust real-world evidence collection with targeted clinical programs can address payer concerns and strengthen clinician confidence. At the same time, clear governance around off-label demand is necessary to maintain safety and professional standards.

In sum, a balanced strategy that emphasizes evidence, device experience, and supply robustness will position organizations to navigate policy shifts, fulfill clinical commitments, and expand access responsibly. Continued cross-sector collaboration and adaptive commercialization models are the most effective means to achieve sustained improvements in patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Human Growth Hormone Market, by Type

  • 8.1. Biosimilar
  • 8.2. Originator

9. Human Growth Hormone Market, by Dosage Form

  • 9.1. Cartridge
  • 9.2. Prefilled Pen
  • 9.3. Vial

10. Human Growth Hormone Market, by Application

  • 10.1. Approved Indications
    • 10.1.1. Chronic Kidney Disease
    • 10.1.2. Gh Deficiency
    • 10.1.3. Prader-Willi Syndrome
    • 10.1.4. Small For Gestational Age
    • 10.1.5. Turner Syndrome
  • 10.2. Off Label Use
    • 10.2.1. Anti Aging
    • 10.2.2. Athletic Performance
    • 10.2.3. Bodybuilding

11. Human Growth Hormone Market, by End User

  • 11.1. Home Care Settings
  • 11.2. Hospitals
  • 11.3. Specialist Clinics

12. Human Growth Hormone Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Human Growth Hormone Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Human Growth Hormone Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Human Growth Hormone Market

16. China Human Growth Hormone Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Biopartners GmbH
  • 17.6. Eli Lilly and Company
  • 17.7. Ferring Pharmaceuticals S.A.
  • 17.8. Genetech Inc.
  • 17.9. Ipsen S.A.
  • 17.10. LG Chem, Ltd.
  • 17.11. Merck KGaA
  • 17.12. Novartis AG
  • 17.13. Novo Nordisk A/S
  • 17.14. Pfizer Inc.
  • 17.15. Roche Holding AG
  • 17.16. Sandoz International GmbH
  • 17.17. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HUMAN GROWTH HORMONE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HUMAN GROWTH HORMONE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES HUMAN GROWTH HORMONE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA HUMAN GROWTH HORMONE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY BIOSIMILAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY BIOSIMILAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY BIOSIMILAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY ORIGINATOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY ORIGINATOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY ORIGINATOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY CARTRIDGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY CARTRIDGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY CARTRIDGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY PREFILLED PEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY PREFILLED PEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY PREFILLED PEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY APPROVED INDICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY APPROVED INDICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY APPROVED INDICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY APPROVED INDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY CHRONIC KIDNEY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY CHRONIC KIDNEY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY CHRONIC KIDNEY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY GH DEFICIENCY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY GH DEFICIENCY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY GH DEFICIENCY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY PRADER-WILLI SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY PRADER-WILLI SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY PRADER-WILLI SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY SMALL FOR GESTATIONAL AGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY SMALL FOR GESTATIONAL AGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY SMALL FOR GESTATIONAL AGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY TURNER SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY TURNER SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY TURNER SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY OFF LABEL USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY OFF LABEL USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY OFF LABEL USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY OFF LABEL USE, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY ANTI AGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY ANTI AGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY ANTI AGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY ATHLETIC PERFORMANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY ATHLETIC PERFORMANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY ATHLETIC PERFORMANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY BODYBUILDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY BODYBUILDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY BODYBUILDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY SPECIALIST CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY SPECIALIST CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY SPECIALIST CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS HUMAN GROWTH HORMONE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS HUMAN GROWTH HORMONE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS HUMAN GROWTH HORMONE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS HUMAN GROWTH HORMONE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS HUMAN GROWTH HORMONE MARKET SIZE, BY APPROVED INDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS HUMAN GROWTH HORMONE MARKET SIZE, BY OFF LABEL USE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS HUMAN GROWTH HORMONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA HUMAN GROWTH HORMONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA HUMAN GROWTH HORMONE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA HUMAN GROWTH HORMONE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA HUMAN GROWTH HORMONE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA HUMAN GROWTH HORMONE MARKET SIZE, BY APPROVED INDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA HUMAN GROWTH HORMONE MARKET SIZE, BY OFF LABEL USE, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA HUMAN GROWTH HORMONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA HUMAN GROWTH HORMONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA HUMAN GROWTH HORMONE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA HUMAN GROWTH HORMONE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA HUMAN GROWTH HORMONE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA HUMAN GROWTH HORMONE MARKET SIZE, BY APPROVED INDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA HUMAN GROWTH HORMONE MARKET SIZE, BY OFF LABEL USE, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA HUMAN GROWTH HORMONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA HUMAN GROWTH HORMONE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA HUMAN GROWTH HORMONE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA HUMAN GROWTH HORMONE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA HUMAN GROWTH HORMONE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA HUMAN GROWTH HORMONE MARKET SIZE, BY APPROVED INDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA HUMAN GROWTH HORMONE MARKET SIZE, BY OFF LABEL USE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA HUMAN GROWTH HORMONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE HUMAN GROWTH HORMONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE HUMAN GROWTH HORMONE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE HUMAN GROWTH HORMONE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE HUMAN GROWTH HORMONE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE HUMAN GROWTH HORMONE MARKET SIZE, BY APPROVED INDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE HUMAN GROWTH HORMONE MARKET SIZE, BY OFF LABEL USE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE HUMAN GROWTH HORMONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST HUMAN GROWTH HORMONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST HUMAN GROWTH HORMONE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST HUMAN GROWTH HORMONE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST HUMAN GROWTH HORMONE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST HUMAN GROWTH HORMONE MARKET SIZE, BY APPROVED INDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST HUMAN GROWTH HORMONE MARKET SIZE, BY OFF LABEL USE, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST HUMAN GROWTH HORMONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA HUMAN GROWTH HORMONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA HUMAN GROWTH HORMONE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA HUMAN GROWTH HORMONE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA HUMAN GROWTH HORMONE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA HUMAN GROWTH HORMONE MARKET SIZE, BY APPROVED INDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA HUMAN GROWTH HORMONE MARKET SIZE, BY OFF LABEL USE, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA HUMAN GROWTH HORMONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET SIZE, BY APPROVED INDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET SIZE, BY OFF LABEL USE, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC HUMAN GROWTH HORMONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN HUMAN GROWTH HORMONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN HUMAN GROWTH HORMONE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN HUMAN GROWTH HORMONE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN HUMAN GROWTH HORMONE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN HUMAN GROWTH HORMONE MARKET SIZE, BY APPROVED INDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN HUMAN GROWTH HORMONE MARKET SIZE, BY OFF LABEL USE, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN HUMAN GROWTH HORMONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. GCC HUMAN GROWTH HORMONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GCC HUMAN GROWTH HORMONE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. GCC HUMAN GROWTH HORMONE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 130. GCC HUMAN GROWTH HORMONE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. GCC HUMAN GROWTH HORMONE MARKET SIZE, BY APPROVED INDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 132. GCC HUMAN GROWTH HORMONE MARKET SIZE, BY OFF LABEL USE, 2018-2032 (USD MILLION)
  • TABLE 133. GCC HUMAN GROWTH HORMONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION HUMAN GROWTH HORMONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION HUMAN GROWTH HORMONE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION HUMAN GROWTH HORMONE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION HUMAN GROWTH HORMONE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION HUMAN GROWTH HORMONE MARKET SIZE, BY APPROVED INDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION HUMAN GROWTH HORMONE MARKET SIZE, BY OFF LABEL USE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION HUMAN GROWTH HORMONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS HUMAN GROWTH HORMONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS HUMAN GROWTH HORMONE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS HUMAN GROWTH HORMONE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS HUMAN GROWTH HORMONE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS HUMAN GROWTH HORMONE MARKET SIZE, BY APPROVED INDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS HUMAN GROWTH HORMONE MARKET SIZE, BY OFF LABEL USE, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS HUMAN GROWTH HORMONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. G7 HUMAN GROWTH HORMONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. G7 HUMAN GROWTH HORMONE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. G7 HUMAN GROWTH HORMONE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 151. G7 HUMAN GROWTH HORMONE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. G7 HUMAN GROWTH HORMONE MARKET SIZE, BY APPROVED INDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 153. G7 HUMAN GROWTH HORMONE MARKET SIZE, BY OFF LABEL USE, 2018-2032 (USD MILLION)
  • TABLE 154. G7 HUMAN GROWTH HORMONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. NATO HUMAN GROWTH HORMONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. NATO HUMAN GROWTH HORMONE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. NATO HUMAN GROWTH HORMONE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 158. NATO HUMAN GROWTH HORMONE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. NATO HUMAN GROWTH HORMONE MARKET SIZE, BY APPROVED INDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 160. NATO HUMAN GROWTH HORMONE MARKET SIZE, BY OFF LABEL USE, 2018-2032 (USD MILLION)
  • TABLE 161. NATO HUMAN GROWTH HORMONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL HUMAN GROWTH HORMONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES HUMAN GROWTH HORMONE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES HUMAN GROWTH HORMONE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES HUMAN GROWTH HORMONE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES HUMAN GROWTH HORMONE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES HUMAN GROWTH HORMONE MARKET SIZE, BY APPROVED INDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES HUMAN GROWTH HORMONE MARKET SIZE, BY OFF LABEL USE, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES HUMAN GROWTH HORMONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA HUMAN GROWTH HORMONE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA HUMAN GROWTH HORMONE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA HUMAN GROWTH HORMONE MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA HUMAN GROWTH HORMONE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA HUMAN GROWTH HORMONE MARKET SIZE, BY APPROVED INDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA HUMAN GROWTH HORMONE MARKET SIZE, BY OFF LABEL USE, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA HUMAN GROWTH HORMONE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)